Spire wins US grants for prostheses coating:
This article was originally published in Clinica
Spire Biomedical is to develop coatings that could reduce the wear of and increase the lifetime of two materials used in hip and knee orthopaedic prostheses - ultra-high molecular weight polyethylene (UHMWPE) and cobalt-chrome metal. Using the company's proprietary ion beam deposition process, UHMWPE will be coated with a tough, biocompatible, ceramic coating while the cobalt chrome component will be treated with a metal matrix composite surface, said Bedford, Massachusetts-based Spire. The company has received two grants totalling $200,000 from the US National Institutes of Health.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.